Implementing Good Clinical Practice at an Academic Research Institution
|
|
- Blanche Silvia Tate
- 5 years ago
- Views:
Transcription
1 Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes
2 Outline Significance of Essential Documents Background Current Practices Composition Maintenance (QI Regulatory Binder) Case Study Resources for Maximizing Quality 2 GCP Conference
3 Significance: Background Pre ICH GCP guidelines Clinical investigations of new drugs were frequently repeated due to inconsistent standards for conducting and documenting clinical research in the international community. This often caused delays in the review and approval process of new drugs. (CITI) Publication of ICH GCP guidelines In 1996, regulatory and pharmaceutical experts from the US, European Union and Japan developed a unified set of standards for clinical trials that streamlined the review and approval process of new drugs. One of the standards was the GCP List of Essential Documents. (CITI) Updated November 2016 to address evolution of studies from paper base to electronic based documentation. 3 GCP Conference
4 Significance: Current Practices PHRC Recordkeeping & Record Retention Requirements Investigators are required to maintain records of their human subject research activities. Good records are essential for verifying the quality of study data produced and demonstrating compliance with good clinical practice guidelines and applicable regulatory requirements (PHRC June 2015) 4 GCP Conference
5 Composition The collection of essential documents in section 8 of the GCP guidelines is divided into 3 subparts based on the point in time they are produced in the clinical trial: Before the clinical phase During the clinical conduct After completion or termination Each subpart is comprised of essential regulatory documents. Document Phases 5 GCP Conference
6 Maintenance QI Regulatory Binder maintains essential regulatory documents for a range of human subject research. The binder also provides: Guidance for organization and recordkeeping Assistance with proper study documentation and successful study management Readily accessible links to on-line resources Available in both print and electronic form QI Regulatory Binder 6 GCP Conference
7 QI Regulatory Binder Consultations Timeline: 01/01/2012 to 06/11/2015 Oth, 1, 3% Requests by Institution BWH, 11, 29% 37 Investigators New to QI: 51% New Investigators 1 : 32% 38 Protocols Non-industry sponsored: 84% MGH, 25, 66% McLean, 1, 2% Full Board: 71% FDA Regulated: 60% 1 Less than 4 IRB approved protocols 7 GCP Conference
8 Regulatory Binder Guidelines 1. Establish the binder at the beginning of the study prior to subject enrollment. 2. Add study staff maintaining the binder to the IRB protocol. 3. Store binder in a safe and secure location that is accessible to all study staff. 4. Customize the binder to meet the needs of your protocol. 8 GCP Conference
9 Regulatory Binder Sections All Studies Protocol Staff CVs* Staff Licensures* Logs IRB Documents Consent Forms Data Collection *for studies involving an intervention or interaction with subjects Study Specific Lab Documents NIH Sponsor Drug/Device FDA Financial Disclosure DSMB 9 GCP Conference
10 Regulatory Documents All Studies Current IRB Approved Protocol* Documents current study objectives and procedures approved by the IRB Staff CVs & Licensures (for interaction/intervention studies) Confirms staff qualifications to conduct a study or perform delegated tasks Logs Assists with study management and collection of data reported to regulatory authorities IRB Documents* Demonstrates that appropriate regulatory authorities have reviewed and approved the study prior to initiation Current IRB Approved Consent Form(s)* Documents that the informed consent process and information given to subjects were reviewed and approved by the IRB Data Collection* *can be retained in Insight if after April 2013 Template forms used to collect study data 10 GCP Conference
11 Study Management Tools/Logs Maintain logs for all studies as applicable: Enrollment/screening Delegation of responsibility/signature Monitoring Drug/device dispensing & accountability AE tracking Minor deviations QI template logs: ces/rsm/rsf/pages/study-management-tools.aspx 11 GCP Conference
12 Study Management Tools REDCap ebinder The Electronic Regulatory Binder is a project within REDCap that was developed by Partners Human Research Quality Improvement (QI) Program and Enterprise Research Infrastructure & Services (ERIS). To request a copy of the project for an IRB approved protocol: log into REDCap with your Partners username and password, click the tab titled Create New Project and complete the fields for requesting the Electronic Regulatory Binder template. General instructions for using the project to enter and store regulatory information can be found on the project s homepage. 12 GCP Conference
13 Regulatory Documents Study Specific Laboratory Verifies the competency of lab facilities and the reliability of test results (CLIA/CAP Certificate, Lab Director s CV, normal range values) Sponsor Documents significant discussions between the sponsor and site regarding the administration and conduct of trial Drug/Device Provides relevant & current scientific information about the drug/device and its use in subjects FDA Confirms compliance with FDA regulations governing the use of investigational products Financial Disclosure Documents financial agreements between clinical investigators and the sponsor of the trial (FDA form 3455) DSMP Data Monitoring plan; Reports and Minutes from Data Safety Monitoring Board meetings, if applicable 13 GCP Conference
14 November 2016 GCP Guideline Revisions The location of essential documents should be centralized and documented Certification of copies of original documents SOPs should be established and adhered to. Document staff creating copies. Staff should attest that copies are full and complete reproductions of original documents Investigator should have control of and continuous access to study data and essential documents 14 GCP Conference
15 Record Retention HRC 7 years upon completion of the study FDA 2 years after the marketing permit application is approved or terminated At the end of the study when the FDA is notified that test articles were disposed or returned and a marketing permit is sought Industry standard 15 years 15 GCP Conference
16 Case Study Dr. Chang is the site principal investigator for a Phase III study assessing the safety and efficacy of Doximab, an injectable medication, for the treatment of moderate to severe Crohn s disease. Per IRB approved protocol, Dr. Chang is responsible for oversight of the protocol, determination of subject eligibility and monitoring of study data to ensure subject safety and data integrity. In an effort to assist the PI, Sally Perkins, the coordinator, completed the eligibility assessments and conducted all study visits, except those that required a physical exam. Sally who was not trained in medical terminology also completed case report forms although she had difficulty interpreting all of the acronyms on the forms. The monitor reviewed the study documentation remotely twice a year.
17 Case Study Continued Dr. Chang s study was inspected by the FDA. The FDA found the following deficiencies: 1. You failed to conduct the studies according to the signed investigator statement [21 CFR ]. 2. You failed to conduct the study in accordance with the investigational plan and protocol [21 CFR ]. 3. You failed to maintain adequate and accurate case histories that record all observations and other data pertinent to the investigation on each individual administered the investigational drug or employed as a control in the investigation [21 CFR (b)]. Questions Which actions led to each of the FDA s findings? Is the coordinator going to be held responsible for any of findings in the FDA Form 483? 17 GCP Conference
18 Consequences of noncompliance IRB Requirements to report noncompliance to the IRB Reports to OHRP, FDA Suspension or restriction of research priveleges Internal effort to investigate, respond and report: IRB, QI Program, Institutional Official, Office of General Counsel FDA enforcement Inspection Warning letter, Disqualification, Monetary fines, Civil/Criminal liability 18 GCP Conference
19 Resources for Maximizing Quality Checklists QI Regulatory Binder Study Start-up Checklist for Minimal Risk Resea rch Self-Assessment Checklist (revisions in progress) Activities/Services Regulatory Binder Consultations Assistance with FDA Applications (IND/IDE) In-services On-site reviews Contact QI Program 19 GCP Conference
20 Questions 20 GCP Conference
21 References International Conference on Harmonization. (1996). E6 Guideline for Good Clinical Practice. Retrieved from Partners Human Research Committee. (2015). Guidance for Investigators Recordkeeping and Record Retention Requirements. Retrieved from Partners Human Research Committee. (2007). Principal Investigators and Delegation of Study- Related Tasks to Co-Investigators and Study Staff. Retrieved from Partners Human Research Committee. (2005). Data and Safety Monitoring Plans in Human- Subjects Research. Retrieved from Code of Federal Regulations. (2012). 21 CFR 312 Investigational New Drug Application. Retrieved from Code of Federal Regulations. (2012). 21 CFR 812 Investigational Device Exemptions. Retrieved from GCP Conference 21
22 Hyperlink Slides
23 23 GCP Conference
24 Approved Consent Form Original Consent Form Subject Population: Adults under going xxx procedure IRB Protocol Number: 2004p Sponsor Protocol Number: Consent Form Valid Date: November 25, 2007 Amendment Number: IRB Expiration Date: November 1, 2008 Amendment Approval Date: November 25, 2007 An amendment to change the consent form was approved on March 2, 2008 Subject Population: Adults under going X procedure IRB Protocol Number: 2004p Consent Form Valid Date: March 2, 2008 IRB Expiration Date: November 1, GCP Conference
25 Data Collection Terms Source Documentation: Data Collection Sheet: First recording of any observations or data about a subject (Clinical Research Coordinator Handbook). (e.g., Hospital records/medical records, Lab reports, Subject diaries, Evaluation checklists, X-rays, Physician s progress notes, EKG Report) Pre-designed forms or templates used by the site to collect information about subjects (e.g., pain assessment scale, vital signs sheet) Case Report Form (CRFs) : Provide for the orderly transfer of data from the study site to the CRO/SMO or Sponsor (Clinical Research Coordinator Handbook). 25 GCP Conference
26 PHRC Guidelines: Delegation of Responsibility Principal investigators must ensure that designated individuals: 1. Are qualified to perform tasks 2. Receive adequate training 3. Have adequate supervision When delegating tasks that are clinical or medical in nature, the principal investigator must ensure that the individual has the relevant formal medical training. Investigators are advised to maintain a list of qualified staff and their delegated tasks. 26 GCP Conference
27 Product Information Drug Investigator Brochure Description of the drug and formula Pharmacological and toxicological effects Pharmacokinetics and biological disposition Safety and effectiveness Risks and side effects (21 CFR ) Package Insert Device Manual Device Information for Use 27 GCP Conference
28 Drug/Device Accountability Protocol identifier (number, title) Subject identifiers (initials/study number) Randomization and/or kit number Date dispensed/implanted Amount dispensed Date returned/destroyed Amount returned Initials of person dispensing/implanting/receiving QI Drug Accountability Log 28 GCP Conference
29 FDA (IND/IDE Studies) Clinical Investigator (conducts study) 1. Signed Investigator Agreement 2. FDA Financial Disclosures 3. Serious adverse events submitted to the sponsor Sponsor-Investigator (initiates and conducts study) 1. Clinical Investigator requirements 1 or 2 and 3 2. Original application and all subsequent submissions to the FDA FDA 1571 (drug) IND/IDE Application Amendments to application Adverse Event Reports Annual Reports 3. Certification of Registration to Clinical Trials. Gov (Form 3674) 29 GCP Conference
30 Signed Agreement FDA 1572 (drug) Investigator Agreement (device) Identifies facilities, IRB and investigators. Investigator agreement to conduct research according to 21 CFR 312: i. I agree to conduct the study(ies) in accordance with the relevant, current protocol(s) and will only make changes in a protocol after notifying the sponsor, except when necessary to protect the safety, rights, or welfare of subjects. ii. iii. iv. I agree to personally conduct or supervise the described investigation(s). I will ensure that the requirements relating to obtaining informed consent in 21 CFR Part 50 and institutional review board (IRB) review and approval in 21 CFR Part 56 are met. I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study(ies) are informed about their obligations in meeting the above commitments. v. I agree to maintain adequate and accurate records in accordance with 21 CFR and to make those records available for inspection in accordance with 21 CFR Investigator agreement to conduct research according to 21 CFR 812 (21 CFR ) 30 GCP Conference
31 Data Safety Monitoring Board A Data Safety Monitoring Board is an independent committee that monitors study data to determine if it is appropriate, from both a scientific and ethical standpoint, to continue the study as planned (PHRC Policy: Data and Safety Monitoring Plans). 31 GCP Conference
FDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationSponsor-Investigator Responsibilities In Clinical Trials
In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.
More informationELEMENTS OF A DATA MONITORING PLAN
ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationSELF-ASSESSMENT CHECKLIST
SELF-ASSESSMENT CHECKLIST SECTION 1: REGULATORY DOCUMENTATION Staff Documentation 1. Are all versions of the IRB approved protocol on file (including most recent)? 2. Are there CVs/biosketches of PI, Co-Is,
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationRegulatory Binder Guidance
Regulatory Binder Guidance What is the purpose of a regulatory binder? Achieve and maintain regulatory compliance Ensure protection of human subjects and high standards of research Guidance for organization
More informationRegulatory Binder: Set-up and Maintenance
Regulatory Binder: Set-up and Maintenance Introduction Federal and state regulations, institutional policy, and good clinical and research practices require investigators to maintain documents related
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationVCU Faculty Held IND and IDE Procedure Handbook
VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted
More informationRegulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of
More informationORC Sponsor-Investigator IDE Checklist
A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21CFR812. This means that such investigators have additional responsibilities.
More informationHuman Research Protection Program Policy
Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationSource Documents and Regulatory Binders October 6, 2016
Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationIDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES
IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312
More informationHuman Research Protection Program Policy
Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More information1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
More informationRegulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005
Regulatory Document Guidelines for DMID Clinical Studies Version 3.0-5-Oct-2005 1 Regulatory File Document Guidelines Purpose: To aid DMID supported Investigators in establishing a file of essential documents
More informationROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn
More informationGuidelines for Setting Up a Regulatory Binder
Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction
More informationClinical Research with Drugs/Biologics and Devices & Good Clinical Practices
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationResearch Professionals Network Workshop Series
Research Professionals Network Workshop Series SO YOU THINK YOU KNOW GCP? Mary-Tara Roth Director, CRRO mtroth@bu.edu Gina Daniels Human Research Quality Manager gdaniels@bu.edu What is [ICH] GCP? an
More informationHuman Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance
Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017 Objectives 1. Understand the purpose of the audit program 2. Identify
More informationPresented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals
ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction
More informationCONTACT INFORMATION. PHRC Office. Josephine O Driscoll-Davis. Michael Ducey
PHRC Office CONTACT INFORMATION 116 Huntington Ave., 10 th Floor Boston, MA 02116 http://healthcare.partners.org/phsirb Josephine O Driscoll-Davis Assistant Director Administrative Chair (617) 424-4107
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More informationInvestigator Site File Index (Medical Devices)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol (Clinical Investigation Plan) Current version plus all previous versions (or provide file note
More informationOFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out
OFFICE FOR RESEACH PROCEDURE Site Initiation and Close-out 1. Purpose: To describe the procedures related to site initiation and close-out of a clinical trial. 2. Scope: Applicable to all phases of clinical
More informationGood Clinical Practice Compliance
Good Clinical Practice Compliance Pharmaceutical Regulatory & Compliance Congress Greg Levine LLP Agenda? GCP compliance rules What is the law? What other (non-binding) standards apply? What are the unwritten
More informationUC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities
UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities BEVERLY ALGER, CCRP, CHRC Research Compliance Officer Office of Research Compliance November 2016
More informationSponsor/Investigator Responsibilities
Sponsor/Investigator Responsibilities Marian Serge, RN Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health Food and Drug Administration Marian.Serge@fda.hhs.gov
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More informationDemystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?
Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination
More informationBACKGROUND PURPOSE 9/24/2009 DATA AND SAFETY MONITORING
DATA AND SAFETY MONITORING September 2009 Joey Casanova, BBA, CIP Human Subject Research Office SECTION 1 BACKGROUND PURPOSE Data and safety monitoring is the process for reviewing accumulated outcome
More informationSponsoring an IND? Ignorance is Not Always Blissful
Translational Science 2013 Navigating The FDA Regulatory Landscape April 19, 2013 Washington D.C. Sponsoring an IND? Ignorance is Not Always Blissful Lisa A. Speicher, Ph.D Director, Clinical Trials Office
More informationShow Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH
Show Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH Speakers Kelly Dornin-Koss, MPPM, RN, CCRC Director Education and Compliance for Human
More informationObjectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder
Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory
More informationInvestigator Site File Index (CTIMP)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol Current version plus all previous versions (or provide file note to detail location of previous
More informationUSE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH
Policy P.11 Written By: B. Laurel Elder Created: June 3, 2013 Edited Replaces 10-9-2009 Version P.11.4 USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH A. Procedure Contents this procedure
More informationFood and Drug Administration Guidance: Supervisory Responsibilities of Investigators
Journal of Diabetes Science and Technology Volume 5, Issue 2, March 2011 Diabetes Technology Society REVIEW ARTICLE Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationI. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationClinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014
Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationGood Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ
Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More information4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.
POLICY #: RCO-203 Page: 1 of 7 1. POLICY STATEMENT: Essential regulatory documents will be on maintained for research sponsored by or conducted at Dana-Farber/Harvard Cancer Center (DF/HCC) to assure compliance
More informationTopics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities
Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,
More informationPreparing for a United States Food and Drug Administration (FDA) Inspection: VOICE
Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE This project has been funded in whole or in part with Federal funds from the Division of AIDS (DAIDS), National Institute
More informationInvestigator Manual. Human Subjects Protection Program
Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the
More informationAPEC GCP Inspection Workshop May 29, 2008
Common Investigator Deficiencies Jean Toth-Allen, Ph.D. APEC GCP Inspection Workshop May 29, 2008 Most Common CI Deficiencies Failure to follow the investigational plan Protocol deviations Inadequate recordkeeping
More informationGCP Convergence Improves Transportability of Medical Device Clinical Data
GCP Convergence Improves Transportability of Medical Device Clinical Data By Harmonization-by-Doing Working Group 4 The safety, performance and effectiveness of medical devices are often evaluated by well-controlled
More informationInvestigational New Drug Application
Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution
More informationInvestigator Manual HRP-103
HRP-103 Revised October 04, 2016 Table of Contents 1. Introduction... 3 A. Scope... 3 B. Purpose of this manual... 3 C. Where to get additional information and answers to questions... 3 E. Human Research
More information1 Purpose. 2 Procedure. Title: FDA-Regulated Research. SOP Number: 1301 Effective Date: June 2, Previous Version Dates:
Previous Version Dates: Title: FDA-Regulated Research SOP Number: 1301 Effective Date: June 2, 2017 1 Purpose FDA regulations apply to research that involves a FDA-regulated test article in a clinical
More informationInvestigator Manual Revised August 19, 2013
Investigator Manual Revised August 19, 2013 Investigator Manual Page 2 of 31 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationTitle: Department: Approved by: Director, Human Research Review and Compliance
Title: Department: Requirements for Investigational New Drug (IND) for Human- Subjects Research Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners HealthCare
More informationInvestigational New Drug Development Steps for CRCs
Investigational New Drug Development Steps for CRCs Natalie Nardone, PhD Program Manager, Department of Medicine CRC Instructor, Office of Clinical Research Contact: natalie.nardone@ucsf.edu Learning Objectives
More informationTOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH
Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:
More informationStandard Operating Procedure
Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if
More informationKathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration
Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration Kathy.Weil@fda.hhs.gov Follow the protocol and IDE regulations
More information1.0 INTRODUCTION AND OVERVIEW
Table of Contents 1.0 INTRODUCTION AND OVERVIEW... 3 2.0 DEFINITIONS... 4 3.0 OVERSIGHT AND ORGANIZATION... 5 3.1 CLINICAL RESEARCH OVERSIGHT COMMITTEE (CROC)... 5 3.2 CLINICAL RESEARCH SUPPORT (CRS)...
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More information11.0 FDA-Regulated Research
11.0 FDA-Regulated Research The HSC evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationResearch Study Close-down and Archiving Procedures
Title: Research Study Close-down and Archiving Procedures Outcome Statement: To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
More informationRESEARCH AUDIT Standard Operating Procedure
Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor
More informationGCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018
1 GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018 Sumitra Sachidanandan GCP Inspection Consultant Clinical Trials Branch Health Products Regulation Group Health Sciences Authority Singapore
More informationHUMAN RESEARCH PROTECTION PROGRAM PLAN
HUMAN RESEARCH PROTECTION PROGRAM PLAN HRP 101 June 2017 706-542-3199 irb@uga.edu https://research.uga.edu/hso/ Table of Contents Scope... 2 Purpose... 2 Definitions... 2 Agent... 2 Clinical Trial... 2
More informationPreparing for Close-Out of Studies and Sites
Preparing for Close-Out of Studies and Sites Presented by: Christie Thomas, MPH, CCRA Matthew Wright, BS, CCRP Dikla Blumberg, PhD CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationLouise Brook Clinical Trials Quality Monitor. Date
Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person
More informationESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL
ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL THIS INFORMATION SHEET (ISR-RG-014) HAS BEEN TAKEN DIRECTLY FROM THE ICH- GUIDELINE* WITH ADDITIONAL COMMENTS ADDED BY THE RESEARCH GOVERNANCE
More informationHub Performance Assessment
Hub Performance Assessment Hub complex performance assessment will be assessed with a standardized report card mechanism. The report card draws on data quality reports, enrollment reports, and monitoring
More informationLOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office
LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough
More informationSTANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File
Research Department STANDARD OPERATING PROCEDURE STH Researcher SOP History CSUH 00/016 SOP Number A116 Created STH Research Department (TL) Reviewed by STH Research Department (AL) 06 August 2009 Superseded
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)
More informationGuidance on Requirements of the Sponsor and the Investigator as a Sponsor
Guidance on Requirements of the Sponsor and the Investigator as a Sponsor University of Colorado Denver (UCD) secures assurances from the sponsor or the investigator-sponsor* that the manufacture and formulation
More informationStandard Operating Procedures (SOPs)
Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More information13.0 Quality Improvement in the HRPP Program
13.0 Quality Improvement in the HRPP Program 13.1 Definitions Quality Improvement: A process initiated to develop/enhance a practice or procedure and to institutionalize the practice or procedure. Audit:
More informationPOLICY AND PROCEDURE MANUAL
POLICY AND PROCEDURE MANUAL PBRC: POLICY NO. 378.00 ORIGIN DATE: 5/25/2016 IMPACTS: CLINICAL RESEARCH LAST REVISED: 1/1/2017 SUBJECT: SOURCE: PURPOSE PENNINGTON BIOMEDICAL CLINICALTRIALS.GOV POLICY INSTITUTIONAL
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationUS Special Operations Command Human Research Protection Office
S- US Special Operations Command Human Research Protection Office Human Research Protocol Submission Form for Headquarters Level Administrative Review of Extramural* Research PURPOSE: All United States
More informationTITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19
POLICY #: MULTI-100 Page: 1 of 4 1. POLICY STATEMENT: The DF/HCC Sponsor-Investigator, Coordinating Center and External Sites collaborating in DF/HCC Investigator-Sponsored Multi-Center research must comply
More information